Inhibition of A2AR by AZD4635 induces anti-tumor immunity alone and in combination with anti-PD-L1 in preclinical models

被引：6

作者：

Borodovsky, Alexandra ^{[1
]}

Wang, Yanjun ^{[1
]}

Ye, Minwei ^{[1
]}

Shaw, Joseph C. ^{[1
]}

Sachsenmeier, Kris ^{[1
]}

Deng, Nanhua ^{[1
]}

Goodwin, Kelly ^{[1
]}

Clarke, James D. ^{[1
]}

Goodwin, Richard ^{[1
]}

Strittmatter, Nicole ^{[1
]}

Hay, Carl ^{[2
]}

Sah, Vasu ^{[1
]}

Deborah, Lawson ^{[1
]}

Reimer, Corinne ^{[1
]}

Congreve, Miles ^{[3
]}

Mason, Jonathan ^{[3
]}

Marshall, Fiona ^{[3
]}

Lyne, Paul ^{[1
]}

Woessner, Richard ^{[1
]}

机构：

[1] AstraZeneca, Boston, MA USA

[2] MedImmune, Gaithersburg, MD USA

[3] Heptares Therapeut, Welwyn Garden City, Herts, England

来源：

CANCER RESEARCH | 2018年 / 78卷 / 13期

关键词：

D O I：

10.1158/1538-7445.AM2018-3751

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3751

引用

页数：2

共 50 条

[21] Tusamitamab ravtansine induces immunogenic cell death and synergizes with anti-PD-1 or anti-PD-L1 antibody combination in solid tumor
Nicolazzi, Celine
Lefebvre, Anne-Marie
Moindrot, Nicolas
Larois, Christelle
Classe, Marion
Sidhu, Sukhvinder
CANCER RESEARCH, 2024, 84 (06)
[22] Normalization of tumor stroma improves the anti-tumor activity of anti-PD-L1 peptides in pancreatic cancer
Lin, Chien-Yu
Cheng, Kun
CANCER RESEARCH, 2022, 82 (12)
[23] Targeting glycosylated PD-1 induces potent anti-tumor immunity
Wang, Yuhan
Sun, Linlin
Yang, Riyao
Liu, Jielin
Qiu, Yufan
Hsu, Jennifer L.
Cha, Jong-ho
Chan, Li-Chuan
Hsu, Jung-Mao
Lee, Heng-Huan
Lai, Yun-Ju
Khoo, Kay-Hooi
Chung, Ezra M.
Li, Chia-Wei
Kim, Yong-Soo
Park, Andrew H.
Yang, Yi
Yoo, Stephen S.
Hung, Mien-Chie
CANCER RESEARCH, 2020, 80 (16)
[24] Preparation and anti-tumor ability evaluation of anti-PD-L1 conjugated curcumin in colon cancer
Ding, Jie
Liu, Zhenhua
Liu, Sheng
Xie, Xueqing
Yin, Qingling
Lu, Wei
Wang, Wanchuan
Zhang, Yi
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2025, 306
[25] Adenosine A2A receptor antagonist, CPI-444, blocks adenosine-mediated T cell suppression and exhibits anti-tumor activity alone and in combination with anti-PD-1 and anti-PD-L1
Willingham, S.
Ho, P.
Leone, R.
Choy, C.
Powell, J.
McCaffery, I.
Miller, R.
ANNALS OF ONCOLOGY, 2016, 27
[26] Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
Ray, A.
Das, D. S.
Song, Y.
Hideshima, T.
Tai, Y-T
Chauhan, D.
Anderson, K. C.
LEUKEMIA, 2018, 32 (03) : 843 - 846
[27] Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma
A Ray
D S Das
Y Song
T Hideshima
Y-T Tai
D Chauhan
K C Anderson
Leukemia, 2018, 32 : 843 - 846
[28] ANTI-PD-L1/IL-15 KD033 ACTIVATED MACROPHAGES AND INDUCED ANTI-TUMOR IMMUNITY IN THE TUMOR-MICROENVIRONMENT
Martomo, Stella
Wang, George
Polonskaya, Zhanna
Luna, Xenia
Lu, Dan
Patel, Jeegar
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A681 - A681
[29] The A2AR antagonist AZD4635 prevents adenosine-mediated immunosuppression in tumor microenvironment and enhances antitumor immunity partly by enhancing CD103+dendritic cells.
Chandra, Dinesh
Barbon, Christine M.
Borodovsky, Alexandra
Wang, Yanjun
Ye, Minwei
Prickett, Laura
Sachsenmeier, Kris
Shao, Wenlin
Barrett, Carl
Fawell, Stephen
Mele, Deanna A.
Schuller, Alwin
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) : 74 - 75
[30] Anti-PD-L1 and lenalidomide enhance anti-tumor immunity in cutaneous T cell lymphoma through targeting PD1+M2-like tumor-associated macrophages
Querfeld, Christiane
Wu, Xiwei
Qin, Hanjun
Yuan, Yate-Ching
Su, Chingyu
Zain, Jasmine
Feng, Mingye
Rosen, Steven
Han, Zhen
EUROPEAN JOURNAL OF CANCER, 2023, 190 : S4 - S4

← 1 2 3 4 5 →